<DOC>
	<DOCNO>NCT02362503</DOCNO>
	<brief_summary>The purpose study determine whether BMS Attachment Inhibitor ( BMS-663068 ) effective treatment heavily treatment experienced HIV-1 patient multi-drug resistance .</brief_summary>
	<brief_title>Attachment Inhibitor Comparison Heavily Treatment Experienced Patients</brief_title>
	<detailed_description />
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Men nonpregnant woman chronic HIV1 infection Antiretroviralexperienced document historical baseline resistance , intolerability , and/or contraindication antiretrovirals least three class Failing current antiretroviral regimen confirm plasma HIV1 RNA ≥ 400 c/mL ( first value Investigator , second Screening lab ) Must ≤ 2 class least 1 2 fullyactive antiretrovirals remain effectively combine form viable new regimen , base current and/or document historical resistance test tolerability safety Able receive ≥ 1 fully active approve antiretroviral part OBT Day 9 onwards Randomized Cohort Subjects without remain fully active approve antiretroviral may enrol NonRandomized Cohort Chronic untreated Hepatitis B virus ( HBV ) ( however , patient chronic treat HBV eligible ) HIV2 infection Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 7 x ULN Alkaline Phosphatase &gt; 5 x ULN Bilirubin ≥ 1.5 x Upper limit normal ( ULN ) ( unless subject currently atazanavir predominantly unconjugated hyperbilirubinemia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>